MARTINSRIED/MUNICH, Germany, May 30 /PRNewswire-FirstCall/ -- U.S.
Research and Development Facilities in Waltham/Boston, Mass. and Princeton,
N.J., -- GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; Nasdaq:
GPCB) today announced that the Company will be presenting at the 8th German
Corporate Conference in Frankfurt, Germany. The German Corporate Conference is
organized by Deutsche Bank and provides institutional investors with the
opportunity to hear presentations from more than 100 of the most important
companies in the German market.
The presentation will be given by Mirko Scherer, Ph.D., Chief Financial
Officer of GPC Biotech, and is scheduled for Wednesday, June 1, 2005 at 14:00
CET/8 AM EDT at The Hilton Frankfurt.
The presentation will be webcast live and will be accessible through the
GPC Biotech Web site at http://www.gpc-biotech.com. A replay will be available
via the Web site following the live event.
GPC Biotech AG is a biopharmaceutical company discovering and developing
new anticancer drugs. The Company's lead product candidate -- satraplatin --
is currently in a Phase 3 registrational trial as a second-line chemotherapy
treatment in hormone-refractory prostate cancer following successful
completion of a Special Protocol Assessment by the U.S. FDA and receipt of a
Scientific Advice letter from the European central regulatory authority, EMEA.
The FDA has also granted fast track designation to satraplatin for this
indication. Satraplatin was in-licensed from Spectrum Pharmaceuticals, Inc.
Other anticancer programs include: a monoclonal antibody with a novel
mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1
clinical development, and a small molecule broad-spectrum cell cycle
inhibitor, currently in pre-clinical development. The Company is leveraging
its drug discovery technologies to elucidate the mechanisms-of-action of drug
candidates and to support the growth of its drug pipeline. GPC Biotech also
has a multi-year alliance with ALTANA Pharma AG working with the ALTANA
Research Institute in the U.S., which provides GPC Biotech with revenues
through mid-2007. GPC Biotech AG is headquartered in Martinsried/Munich
(Germany). The Company's wholly owned U.S. subsidiary has research and
development sites in Waltham, Massachusetts and Princeton, New Jersey. For
additional information, please visit the Company's Web site at
http://www.gpc-biotech.com.
For further information, please contact:
GPC Biotech AG
Martin Braendle
Associate Director, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565-2600 X2693
ir@gpc-biotech.com
In the U.S.:
Laurie Doyle
Associate Director, Investor Relations & Corporate Communications
Phone: +1 781-890-9007 X267
usinvestors@gpc-biotech.com
SOURCE GPC Biotech AG
 back to top
Related links:
http://www.gpc-biotech.com
CONTACT:
Martin Braendle, Associate Director, Investor
Relations & Corporate Communications, +49 (0)89 8565-2600 ext.
2693, ir@gpc-biotech.com, or In the U.S.: Laurie Doyle, Associate
Director, Investor Relations & Corporate Communications,
+1-781-890-9007 ext. 267, usinvestors@gpc-biotech.com, both of
GPC Biotech
|
